Enfortumab Vedotin

證據等級: L5

預測適應症: 10 個

Enfortumab Vedotin: From Urothelial Carcinoma to HER2-Positive Breast Carcinoma

One-Sentence Summary

Enfortumab vedotin (EV) is a Nectin-4–targeting antibody-drug conjugate (ADC) with MMAE payload, approved for locally advanced or metastatic urothelial carcinoma in the US and EU, but not yet marketed in Canada. Among 10 TxGNN-predicted new indications, HER2-positive breast carcinoma (rank 10, score 98.99%) is the only clinically plausible candidate — supported by 1 active Phase 2 basket trial (EV-202, NCT04225117, n=329) and 4 relevant publications — while the top 9 predictions are mechanistically implausible or represent non-human disease artifacts in the knowledge graph. Current evidence level is L3, and the recommendation is Hold pending Nectin-4 expression profiling in HER2-positive breast cancer populations and maturation of EV-202 cohort data.

Quick Overview

Item	Content
Original Indication	Locally advanced or metastatic urothelial carcinoma (bladder cancer)
Most Actionable Predicted Indication	HER2-Positive Breast Carcinoma (TxGNN Rank 10)
TxGNN Prediction Score	98.99% (HER2+ breast carcinoma); 99.53–99.13% (ranks 1–9, all model artifacts)
Evidence Level	L3 (HER2+ breast carcinoma); L5 (all other predictions)
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Hold

⚠️ Prediction Quality Alert

9 of 10 TxGNN predictions are mechanistically implausible or represent knowledge-graph artifacts. This is an unusual evidence pack and the primary analysis below focuses on rank 10 (HER2-positive breast carcinoma) — the only prediction with clinical plausibility and direct trial evidence.

Rank	Disease	Prediction Issue
1	Leprosy	Mycobacterial infection — no known link to Nectin-4 or MMAE mechanism
2	Multiple endocrine neoplasia	RET/MEN1-driven tumours; minimal Nectin-4 expression evidence
3	Cytomegalovirus infection	DNA virus; measles virus (not CMV) uses Nectin-4 as cell entry receptor — likely KG node confusion
4	Candidiasis	Fungal infection; only literature found is an ADC safety/FAERS adverse event report, not efficacy data
5	Cerebral infarction	Ischemic vascular disease; MMAE causes peripheral neurotoxicity, not neuroprotection
6	HIV infectious disease	CD4+ T-cell–targeting retrovirus; no Nectin-4 antiviral rationale exists
7	Homozygous familial hypercholesterolemia	LDL receptor gene disease; no mechanistic intersection with Nectin-4 signalling
8	Infectious bovine rhinotracheitis	Veterinary disease (BoHV-1 in cattle) — cross-species KG leakage
9	Malignant catarrh	Veterinary disease (ruminant herpesvirus) — cross-species KG leakage
10	HER2-positive breast carcinoma	✓ Mechanistically plausible — see full analysis below

Ranks 8–9 are non-human diseases and must be excluded from all repurposing consideration. The KG species-filtering pipeline requires a systematic fix to prevent future cross-species predictions in human drug repurposing outputs.

Why Is This Prediction Reasonable?

Enfortumab vedotin is an antibody-drug conjugate in which an anti-Nectin-4 monoclonal antibody is site-specifically linked to MMAE (monomethyl auristatin E), a microtubule-disrupting agent. Although formal MOA documentation is not available in this Evidence Pack, EV’s mechanism is well-characterized: following antibody binding to Nectin-4 on the tumour cell surface, the conjugate is internalised and MMAE is released to block mitosis in rapidly dividing cells. The antibody functions as a precision delivery vehicle; MMAE provides the cytotoxic kill.

Nectin-4 is not exclusively a urothelial antigen. Immunohistochemical studies have reported Nectin-4 expression in approximately 50–65% of HER2-positive breast cancers, and emerging data suggest cross-regulatory interactions between Nectin-4 and the HER2/ERBB2 signalling axis. This biological overlap — combined with MMAE’s potent activity against rapidly proliferating, HER2-overexpressing cancer cells — provides a mechanistic rationale for EV’s potential in this population. The EV-202 Phase 2 basket trial (NCT04225117) has directly enrolled patients with HER2-positive solid tumours, generating the first clinical signals.

However, HER2-positive breast cancer is already served by multiple ADC options, including trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). EV’s clinical positioning in this indication would most likely be among patients with confirmed Nectin-4 IHC positivity who have progressed on or are ineligible for HER2-targeted ADCs — a defined but narrow niche that requires prospective patient selection data to characterise.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04225117	Phase 2	Active, Not Recruiting	329	EV-202 basket trial — primary evidence. Evaluates EV as monotherapy (cohorts 1–8) and EV + pembrolizumab (cohort 9) across multiple solid tumours including HER2-positive disease. Primary endpoint: confirmed ORR per RECIST v1.1. Data maturation expected by September 2026.
NCT07287995	Phase 1b/2	Recruiting	428	ASP2998 (anti-TROP2 ADC) as monotherapy and in combination with EV or pembrolizumab in advanced solid tumours. EV serves as a combination partner here; this trial reflects the competitive ADC landscape rather than providing direct EV-in-HER2+ evidence.
NCT07309770	Phase 2	Recruiting	90	Trastuzumab Rezetecan (HER2-targeting ADC) in HER2-positive solid tumours including urothelial carcinoma. Competitive landscape reference; drug candidate is not EV.
NCT05097599	Phase 2	Terminated	11	StrataPATH biomarker-guided basket trial of approved drugs in new populations. Terminated early with only 11 participants enrolled — insufficient sample size for any meaningful efficacy signal.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41654096	2026	Narrative Systematic Review	Critical Reviews in Oncology/Hematology	Synthesises real-world evidence for 10 recently approved oncology drugs; contextualises how EV’s RCT-derived benefit-risk profile translates to broader populations including older adults and patients with comorbidities — relevant for anticipating off-label use patterns
40614854	2025	Translational/Basic Research	Cancer Letters	Polyploid giant cancer cells (PGCCs) mediate resistance to HER2-directed ADCs (T-DM1, T-DXd, disitamab vedotin) in HER2-positive breast and gastric cancer cell lines; highlights a resistance mechanism EV may encounter in HER2+ breast cancer and suggests combination strategies to explore
32315240	2020	Review	ASCO Educational Book	Comprehensive framework for ADC target selection (target expression, antibody, linker, payload); positions Nectin-4 and MMAE within the broader ADC landscape and contextualises EV’s design rationale
41384708	2026	Review	Histopathology	Molecular pathology of bladder cancer covering Nectin-4 expression, KMT2D/KDM6A/TP53/FGFR3 mutational landscape, and personalised oncology classification; background reference for EV’s primary indication rather than direct HER2+ breast cancer evidence

Cytotoxicity

Item	Content
Cytotoxicity Classification	ADC with conventional cytotoxic payload — MMAE (monomethyl auristatin E) is a microtubule inhibitor (auristatin class); overall categorised as targeted-delivery cytotoxic chemotherapy
Myelosuppression Risk	Moderate-to-High — MMAE bystander effect causes neutropenia, anaemia, and thrombocytopenia; dose reductions frequently required in urothelial carcinoma trials
Emetogenicity Classification	Low to Moderate
Monitoring Items	CBC with differential (each cycle), LFTs (ALT/AST/bilirubin), fasting blood glucose (hyperglycaemia risk), peripheral neuropathy grading (neurological assessment each visit), skin inspection (severe cutaneous reactions including SJS/TEN reported)
Handling Protection	Must follow cytotoxic drug handling regulations; as a biohazardous ADC, EV requires pharmacist-prepared closed-system transfer device (CSTD) and dedicated disposal procedures

Safety Considerations

All warning and contraindication data returned as unavailable in this Evidence Pack. Please refer to the approved prescribing information — US FDA label or EMA SmPC for Enfortumab Vedotin — for complete safety information, including boxed warnings for peripheral neuropathy, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), hyperglycaemia, and pneumonitis.

Conclusion and Next Steps

Decision: Hold

Rationale: Of 10 TxGNN predictions, only HER2-positive breast carcinoma (rank 10) is mechanistically supportable: Nectin-4 is expressed in approximately half of HER2-positive breast tumours, and the EV-202 Phase 2 basket trial (NCT04225117) has already enrolled patients in this space. However, the prediction score hierarchy in this evidence pack is inverted — the 9 higher-ranked predictions are false positives, including 2 veterinary diseases, which raises questions about the KG filtering pipeline. Until EV-202 cohort-level efficacy data matures and prospective Nectin-4 IHC data in HER2+ breast cancer is available, proceeding is premature.

To proceed, the following is needed:

Nectin-4 IHC data: Prospective expression profiling in HER2-positive breast cancer patients to confirm target-positive population and define a patient selection strategy
EV-202 results: Outcome data from NCT04225117 HER2-positive solid tumour cohorts, expected by Q3 2026
Competitive differentiation: Clear clinical positioning against T-DM1 and T-DXd — define the specific line of therapy and biomarker criteria (Nectin-4+ / HER2-targeted ADC failure) where EV adds value
Health Canada regulatory pathway: EV does not currently hold a Canadian DIN even for its primary urothelial carcinoma indication; a regulatory filing strategy for Canada is a prerequisite before any off-label use discussion
KG pipeline fix: Implement cross-species filtering in the TxGNN knowledge graph to exclude veterinary diseases (IBR, malignant catarrh) from future human drug repurposing outputs; audit other predictions for similar leakage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.